RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire-AsiaNet / -- U.S. Phase 3 study underway to evaluate RHB-204 as a first-line, stand-alone, oral treatment for pulmonary NTM disease - a rare condition with no FDA-approved first-line therapy FDA Fast Track designation, together with previously granted QIDP...
Authors: LATEST ASIANET NEWS RELEASES